drugset / Trial / NCT05986162
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
RandomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.
Timeline
- Start
- 2023-12-30
- Primary completion
- 2025-05-03
- Completion
- 2025-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itolizumab | Monoclonal antibody | 25 mg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 100 mg | Intravenous |